Introduction {#S1}
============

*Escherichia coli* and *Klebsiella pneumoniae* are the most common species causing Gram-negative sepsis ([@B16]). The increasing incidence of multidrug-resistant (MDR) *E. coli* and *K. pneumoniae* strains has complicated the treatment of Gram-negative sepsis and other invasive infections. Among MDR bacteria, carbapenemase-producing Enterobacterales (CPE) are a major threat to our health system, because of resistance to most or all β-lactam antibiotics and a lack of therapeutic options. As a consequence, the mortality in patients infected with CPE is 26--44% higher than in patients infected with carbapenem-susceptible isolates ([@B13]).

Among the different carbapenemases, OXA-48 has been particularly successful and is the most common carbapenemase in Germany. It has rapidly disseminated from Europe and the Middle East to every continent ([@B6]). OXA-48 is most frequently detected in *K. pneumoniae* and *E. coli*, but can also occur in other Enterobacterales ([@B23]; [@B28]). The β-lactamase gene (*bla*) encoding OXA-48 (*bla*~OXA--48~) is usually located on plasmids (pOXA-48) and bracketed by two identical insertion sequences, IS*1999*, forming the composite transposon Tn*1999* ([@B15]; [@B29]). Different variants of OXA-48, commonly referred to as OXA-48-like (e.g., OXA-181, OXA-232), have been described which differ from OXA-48 by several amino acids, but have not spread as successfully as OXA-48 ([@B26]). However, the reasons for the successful dissemination of OXA-48 are currently not fully understood.

Interestingly, virulence has been linked to the presence of *bla*~OXA--48~ in clinical *E. coli* and *K. pneumoniae* isolates. Several studies reported on clinical isolates with an unusual high lethality in murine infection models as well as the presence of genes associated with virulence or host colonization, but the specific role of OXA-48 had not been addressed ([@B3], [@B4]; [@B11]). Since the dissemination is not driven by a single sequence type (ST), it is possible that OXA-48 itself or *bla*~OXA--48~ harboring plasmids contribute to fitness and virulence of clinical isolates which would provide a survival benefit. We therefore investigated if acquisition of *bla*~OXA--48~ carrying plasmids affects fitness or virulence of *E. coli* and *K. pneumoniae*. For this purpose, OXA-48 producing clinical isolates of *E. coli* and *K. pneumoniae* were analyzed by whole genome sequencing (WGS) including single molecule real time sequencing (SMRT). Additionally, factors involved in dissemination and virulence were investigated *in silico*, *in vitro*, and *in vivo*.

Materials and Methods {#S2}
=====================

Clinical Isolates {#S2.SS1}
-----------------

A total of 35 clinical, non-copy *bla*~OXA--48~ carrying *E. coli* and *K. pneumoniae* strains were included, which were isolated in 2010--2017 in two large German tertiary care hospitals (University Hospitals of Cologne and Frankfurt). All isolates were phenotypically characterized and tested for *bla*~OXA--48~ by PCR and Sanger sequencing as described previously ([@B17]; [@B21]; [@B24]). Minimal inhibitory concentrations (MIC) were determined by MIC test strips (Liofilchem, Roseto degli Abruzzi, Italy) and interpreted according to CLSI breakpoints. Multilocus sequence typing (MLST) was performed either by PCR employing the Pasteur scheme^[1](#footnote1){ref-type="fn"}^ or by WGS using the CGE Sequence Typer Tool.

Horizontal Gene Transfer and Analysis of *bla*~OXA--48~ Plasmids {#S2.SS2}
----------------------------------------------------------------

Horizontal gene transfer (HGT) of *bla*~OXA--48~ was evaluated by liquid mating assays using clinical *Enterobacteriaceae* isolates as donors and sodium azide-resistant strains *E. coli* J53 (EC-J53) and *K. pneumoniae* PRZ (KP-PRZ), *Serratia marcescens* PRaT, *Enterobacter cloacae* DdL, and *Citrobacter freundii* ULTN as recipients as described ([@B20]; [@B19]). Transconjugants (Tc) were selected employing chromogenic agar plates containing 20 μg/mL amoxicillin-clavulanate (ACA) and 100 μg/mL sodium azide. Transconjugation frequency was determined by dividing the numbers of Tc by the numbers of donors. Estimation of the *bla*~OXA--48~ carrying plasmid size was done by S1 nuclease digestion and pulsed-field gel electrophoresis (PFGE). PCR and Sanger sequencing was employed to determine the incompatibility group of OXA-48 plasmids ([@B7]) and the Tn*1999* transposon variants ([Supplementary Table 1](#DS1){ref-type="supplementary-material"}).

Next Generation Sequencing and Data Analysis {#S2.SS3}
--------------------------------------------

Whole genome sequencing was carried out using the Illumina MiSeq platform applying a v3 reagent kit (Illumina, San Diego, CA, United States) generating 150 or 250 bp paired-end reads with coverage of ≥50. *De novo* assembly and scaffolding after quality trimming of the reads was conducted using SPAdes v3.12.0 with standard parameters ([@B2]). To generate complete genome sequences, SMRT long-read sequencing (Pacific Biosciences, Menlo Park, CA, United States) in combination with Illumina short-read sequencing was applied in selected isolates as described ([@B35]).

Genomes were annotated using Prokka 1.8 software ([@B34]), and annotation was corrected manually. Genome sequences were visualized using the BRIG-Software and SnapGene^®^ Viewer ([@B1]). Sequence comparison of plasmids was performed and visualized using an in-house Perl script utilizing BLAST. Short reads of isolates harboring the 63 kb IncL plasmid were mapped to the plasmid sequence from EC7215 (NZ_LR025098.1) used as a reference employing Bowtie2 and visualized using Geneious 11.1.5^[2](#footnote2){ref-type="fn"}^ ([@B25]). Fully closed genome sequences were submitted to NCBI GenBank and can be found under accession number [LR025099](LR025099)--[LR025100](LR025100) (KP12536) and [LR025096](LR025096)--[LR025098](LR025098) (EC7215). Screening for virulence genes was performed using *K. pneumoniae* BIGS database, VFDB^[3](#footnote3){ref-type="fn"}^ and a database which was created based on selected publications ([Supplementary Figures 1](#DS1){ref-type="supplementary-material"}, [2](#DS1){ref-type="supplementary-material"}). Antimicrobial resistance genes were identified using the tool ABRicate^[4](#footnote4){ref-type="fn"}^ applying CGE ResFinder database ([@B38]).

Determination of Cytotoxicity {#S2.SS4}
-----------------------------

A549 human lung epithelial cells (ATCC^®^ CCL-185) were grown in RPMI medium (Biochrom GmbH, Berlin, Germany) with 10% fetal calf serum (FCS) (Sigma, Taufkirchen, Germany) at 37°C until almost confluent and infected with bacteria at a multiplicity of infection (MOI) of 100. After 24 h, the supernatant was filtered (0.45 μm) and the lactate dehydrogenase (LDH) activity was determined by spectrophotometry (Cobas 8000, module 701; Roche, Grenzach-Wyhlen, Germany).

Evaluation of *in vivo* Virulence Using the *Galleria mellonella* Infection Model {#S2.SS5}
---------------------------------------------------------------------------------

Larvae of the greater wax moth (*G. mellonella*) were obtained from UK Waxworms (Sheffield, United Kingdom). Infection of larvae, read-out, and controls were performed as previously described ([@B18]). Median lethal doses (LD~50~) were calculated by non-linear regression analysis using GraphPad Prism 5.0 (La Jolla, CA, United States) ([@B19]).

Evaluation of Bacterial Fitness and Plasmid Stability {#S2.SS6}
-----------------------------------------------------

For analysis of non-competitive growth kinetics, brain heart infusion (BHI) broth (Becton Dickinson, Heidelberg, Germany) were inoculated with an overnight culture and incubated at 37°C and shaking until an optical density of 0.5 at 600 nm (OD~600~) was reached. Bacteria were adjusted to an OD~600~ of 1 in phosphate-buffered saline (PBS), serially diluted and inoculated into an aerobe BD Bactec bottle (BD, Heidelberg, Germany), resulting in a final inoculum of 10^3^ colony-forming units (cfu) per bottle. Bacterial growth was recorded for 24 h at 37°C in a Bactec Fx instrument (BD) by measuring the fluorescence intensity every 15 min. The doubling time was calculated using MS Excel and the Solver tool.

To assess the impact of *bla*~OXA--48~ carriage on bacterial fitness, pairwise competition assays with Tc carrying the natural plasmid pOXA-48 from EC7215 were employed. EC-J53 Tc7215 and its parental strain EC-J53 were analyzed as described before ([@B27]; [@B18]). For determination of cfu, serial dilutions of each culture were plated on Mueller Hinton agar (MHA) and MHA containing 12 mg/L ACA (MHA-ACA). Selection rate constant (s) was calculated as described by [@B27] with negative *s*-values indicating a loss of fitness. To estimate plasmid stability, a pure culture of EC-J53 Tc~7215~ and KP-PRZ Tc7215 was cultured under the same conditions as for the pairwise competitions experiments in antibiotic-free medium. The ratio of colonies growing on MHA-ACA compared to antibiotic-free MHA was determined after three transfers at 90 h in triplicate.

Statistical Analysis {#S2.SS7}
--------------------

Categorical variables were compared using the Chi-square or Fisher's exact test where appropriate. Continuous variables were assessed by Mann--Whitney *U* test. A *P*-value of \<0.05 was considered significant.

Ethics Statement {#S2.SS8}
----------------

All bacterial strains were isolated as part of routine microbiological diagnostic and stored in an anonymized database. According to the ethic committee of the Hospital of Johann Wolfgang Goethe-University, Frankfurt am Main, no informed consent or ethical approval of the study is necessary.

Results {#S3}
=======

Whole-Genome Sequencing and Molecular Characterization of OXA-48 Producing Clinical Isolates {#S3.SS1}
--------------------------------------------------------------------------------------------

Thirty-five non-copy clinical isolates producing OXA-48 including 15 *E. coli* and 20 *K. pneumoniae* were characterized ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). For *E. coli*, ST38 (*n* = 5) and ST354 (*n* = 4) were the most frequent STs. *E. coli* isolates harbored *bla*~OXA--48~ on a mobilizable plasmid in 10/15 cases. In 6/15 isolates *bla*~OXA--48~ was embedded in a Tn*1999* structure which was located on a 63 kb IncL plasmid, whereas one isolate harbored an IncL plasmid with a size of 75 kb. Three isolates carried IncF plasmids of different sizes (80--89 kb). In five isolates, *bla*~OXA--48~ could be transferred neither by conjugation nor by electroporation, indicating a chromosomal location, which was confirmed by WGS and PCRs amplifying Tn*6237* embedded *bla*~OXA--48~ and the adjacent chromosomal genetic environment ([@B37]).

###### 

Characteristics of OXA-48 harboring *E. coli* isolates.

  **Isolate**   **Genetic support of OXA-48**   **MIC (mg/L)**                                                                                           
  ------------- ------------------------------- ---------------- ------------- --------------- ------------- ---- -------- -------- ------ ------ ------ ------
  **EC1027**    297                             666              Rectal swab   Tn*1999.2*      63 kb         \+   256^H^   16       \>32   \>32   16     \>32
  **EC1639**    393                             494              Blood         invTn*1999.2*   63 kb         \+   1        0.25     4      4      0.5    \>32
  **EC2058**    38                              8                Rectal swab   Tn*6237*        Chromosomal   --   64       16       2      0.5    0.25   0.25
  **EC2196**    38                              8                Rectal swab   Tn*6237*        Chromosomal   --   64       2        16     8      2      0.25
  **EC2269**    38                              8                Rectal swab   ΔTn*6237*       Chromosomal   --   64       1        2      2      2      0.25
  **EC2667**    354                             39               Rectal swab   Tn*1999*        63 kb         \+   \>256    \>256    4      4      2      \>32
  EC2700        354                             39               Rectal swab   Tn*1999*        63 kb         \+   256^H^   256^H^   16     16     2      \>32
  **EC3124**    38                              8                Rectal swab   Tn*6237*        Chromosomal   --   256^H^   2        4      4      1      0.25
  EC3239        10                              262              Bile fluid    invTn*1999.2*   75 kb         \+   4        0.5      4      4      2      \>32
  **EC3338**    354                             39               Rectal Swab   ΔTn*6237*       87 kb         --   256^H^   4        2      1      0.25   \>32
  EC3428        38                              8                Rectal swab   Tn*6237*        Chromosomal   --   32       1        2      4      1      0.25
  EC3471        1598                            398              Rectal swab   Tn*1999.2*      63 kb         \+   32       64       1      2      0.25   0.5
  **EC7215**    448                             58               Rectal swab   Tn*1999.2*      63 kb         \+   0.5      0.25     1      1      0.5    \>32
  **EC9629**    354                             39               Blood         ΔTn*6237*       80 kb         --   64       2        1      1      0.5    \>32
  EC14604       1598                            398              Rectal swab   ΔTn*6237*       89 kb         --   \>256    16       0.25   0.5    0.12   0.25

H, heteroresistance; CTX, cefotaxime; CAZ, ceftazidime; ETP, ertapenem; IMP, imipenem; MEM, meropenem; CIP, ciprofloxacin;

a

Isolates which were further assessed in virulence assays are highlighted in bold.

b

Tn

6237

refers to KT444705 (Genbank); ΔTn

6237

of EC2269, EC3338, EC9629, and EC14604 refer to a 19.9 kb fragment of KT444704, KT444705 (Genbank), 3.3 kb fragment of KT444704, and 21.5 kb fragment of KT444705, respectively.

###### 

Characteristics of OXA-48 harboring *K. pneumoniae* isolates.

  **Isolate**   **Genetic support of OXA-48**   **MIC (mg/L)**                                                                            
  ------------- ------------------------------- -------------------- --------------- ------- ---- ---------- ------- ------ ------ ------ -------
  KP659         15                              Stool                Tn*1999.2*      63 kb   \+   \>256      32      \>32   0.5    2      \>32
  **KP920**     16                              Wound swab           Tn*1999.2*      63 kb   \+   \>256      \>256   \>32   \>32   \>32   \>32
  **KP980**     16                              Rectal swab          Tn*1999.2*      63 kb   \+   \>256^H^   16      \>32   2      2      \>32
  KP1151        15                              Rectal swab          Tn*1999.2*      63 kb   \+   \>256      \>256   \>32   \>32   \>32   \>32
  **KP1664**    16                              Throat swab          Tn*1999.2*      63 kb   \+   256^H^     64      32     32     32     \>32
  KP1673        101                             Urine                Tn*1999.2*      63 kb   \+   \>256      \>256   \>32   32     \>32   \>32
  KP1696        377                             Skin swab            invTn*1999.2*   63 kb   \+   \>256      \>256   3      1      1      \>32
  KP1766        1658                            Skin swab            invTn*1999.2*   63 kb   \+   \>256      \>256   \>32   16     32     \>32
  **KP1982**    377                             Wound swab           Tn*1999.2*      63 kb   \+   \>256      \>256   32     8      16     \>32
  **KP2255**    437                             Rectal swab          invTn*1999.2*   63 kb   \+   \>256      128     32     32     32     \>32
  KP2451        392                             Rectal swab          Tn*1999.2*      63 kb   \+   \>256      \>256   2      16     4      \>32
  KP2540        392                             Rectal swab          invTn*1999.2*   63 kb   \+   64         128     2      4      2      \> 32
  **KP2575**    3384                            Rectal swab          Tn*1999*        63 kb   \+   4          2       \>32   8      8      0.06
  **KP2670**    101                             Tracheal secretion   Tn*1999*        63 kb   \+   0.5        0.25    2      2      1      0.03
  **KP2746**    101                             Liver biopsy         invTn*1999.2*   63 kb   \+   2          0.5     16     8      4      0.03
  KP3379        307                             Urine                Tn*1999.2*      63 kb   \+   2          1       4      2      4      16
  KP3907        307                             Stool                Tn*1999.2*      63 kb   \+   \>256      32      \>32   2      1      \>32
  **KP12536**   3385                            Tracheal secretion   Tn*1999.2*      63 kb   \+   0.5        0.25    16     2      4      0.03
  **KP12883**   323                             Urine                invTn*1999.2*   63 kb   \+   0.5        0.25    1      8      1      \>32
  KP13815       11                              Wound swab           Tn*1999.2*      63 kb   \+   \>256      \>256   2      4      2      \>32

H, heteroresistance; CTX, cefotaxime; CAZ, ceftazidime; ETP, ertapenem; IMP, imipenem; MEM, meropenem; CIP, ciprofloxacin;

a

Isolates which were further assessed in virulence assays are highlighted in bold.

In *K. pneumoniae* isolates, STs varied considerably (12 different STs). Strikingly, in all isolates *bla*~OXA--48~ was located on an IncL plasmid with a size of ∼63 kb and embedded in a Tn*1999* family transposon ([Table 2](#T2){ref-type="table"}). Tn*1999.2* was the most common transposon variant (*n* = 12), followed by its inverted version invTn*1999.2* (*n* = 6) and two isolates harboring Tn*1999*.

In 30 of 35 isolates, *bla*~OXA--48~ was identified on plasmids of which 26 were 63 kb IncL plasmids. Of these, five plasmids were completely sequenced by both Illumina^®^ short-read and SMRT long-read technology revealing a sequence identity of each ≥99.9%. To analyze the 63 kb IncL plasmids of the 21 isolates, which were solely sequenced by short-read technology, the sequencing reads of each isolate were mapped to the complete sequence of the 63 kb plasmid IncL from EC7215 ([@B5]). Thereby, a median coverage of \>50 of each isolate to the reference sequence from EC7215 was noticed, suggesting the presence of highly similar plasmids in all these isolates ([Supplementary Figure 1](#DS1){ref-type="supplementary-material"}). The IncL plasmid from EC3239 had a length of 75,552 bp, a sequence identity of \>99% compared to the 63 kb IncL plasmids and carried an additional 8.3 kb Tn*3* transposon and a 4.4 kb fragment of a Col440I plasmid (highest sequence homology to CP039328.1 and AF527822.1, respectively).

The three isolates EC14604, EC3338, and EC9629 harbored *bla*~OXA--48~ on IncF plasmids of different sizes (80--89 kb). The sequences of the plasmids from EC3338 and EC9629 were highly similar and both plasmids shared the same IncF type F-:A1:B32. In contrast, the *bla*~OXA--48~ plasmid from EC14604 had a different IncF type (F2:A-:B-) and displayed a lower sequence similarity compared to the two other EC isolates ([Supplementary Figure 2](#DS1){ref-type="supplementary-material"}). The transposon structures containing *bla*~OXA--48~ on these three IncF plasmids were more diverse compared to the IncL plasmids. The plasmid from EC14604 harbored a 21,571 bp fragment of Tn*6237* in which one of the two copies of the flanking IS*1R* mobile elements was truncated by a Tn*3*-type and a IS*6*-like type insertion element. In EC3338, the *bla*~OXA--48~ plasmid harbored a 12,192 bp fragment of Tn*6237*, flanked on one side by a complete 767 bp IS*1R*-element and a 472 bp fragment of an IS*1R*-element on the other side. The IncF plasmid from isolate EC9629 harbored only a short fragment of Tn*6237* consisting of two copies of IS*1R* sequences up and downstream of *bla*~OXA--48~ and a truncated *lysR* gene.

Antimicrobial susceptibility testing revealed highly variable MICs for carbapenems with meropenem MICs ranging from 0.125 to 16 mg/L in *E. coli* and from 1 to \>32 mg/L in *K. pneumoniae*. Ceftazidime remained susceptible in 8/15 *E. coli* and 4/20 *K. pneumoniae* isolates. Ciprofloxacin resistance was common in both *E. coli* (8/15) and *K. pneumoniae* (16/20). WGS revealed that 8 of 15 *E. coli* isolates carried genes encoding ESBLs, with CTX-M-24 being the most frequent (7/9), and two isolates expressing CMY-42 AmpC β-lactamases, which is in line with the resistance phenotype ([Supplementary Table 2](#DS1){ref-type="supplementary-material"}). Interestingly, CTX-M-15 was present in 13/14 ESBL-producing *K. pneumoniae* isolates but detected in only one strain of *E. coli*, whereas CTX-M-24 was found only in *E. coli*.

Taken together, clinical OXA-48 isolates from Germany are diverse, but mostly carry *bla*~OXA--48~ on a 63 kb sized IncL plasmid. In *K. pneumoniae bla*~OXA--48~ was exclusively linked to a Tn*1999* type transposon and the 63 kb sized IncL plasmid. In *E. coli*, genetic support of *bla*~OXA--48~ was more diverse, but the same 63 kb plasmid was detected in half of the isolates. From the 35 clinical isolates, ten representative *K. pneumoniae* and *E. coli* each were selected based on different criteria (ST type, transposon type, isolation site, and MIC) to study HGT, virulence, and fitness.

Horizontal Gene Transfer of *bla*~OXA--48~ {#S3.SS2}
------------------------------------------

To investigate HGT efficiency of pOXA-48, liquid mating assays were performed using *E. coli* isolates as donors and sodium azide-resistant EC-J53 as a recipient. Except for the five *E. coli* isolates with chromosomal localization of *bla*~OXA--48~, pOXA-48 could be transferred indicating successful intraspecies transconjugation. The conjugation frequency was high for all donors carrying the 63 kb IncL plasmid (median frequency: 1.7 × 10^--1^ ± 3.8 × 10^--1^). In contrast, a significantly lower frequency of 1.5 × 10^--7^ ± 1.9 × 10^--7^ was determined for the isolates with IncF plasmids (*P* \< 0.0001, [Figure 1A](#F1){ref-type="fig"}). In *K. pneumoniae*, pOXA-48 could be transferred to EC-J53 in all cases with a high conjugation frequency of 4.7 × 10^--3^ ± 7.1 × 10^--3^, indicating efficient intergenus transconjugation ([Figure 1B](#F1){ref-type="fig"}). The 63 kb IncL plasmid could furthermore be conjugated from *E. coli* and *K. pneumoniae* into other sodium azide-resistant Enterobacterales species including *K. pneumoniae* PRZ, *S. marcescens* PRaT, *E. cloacae* DdL and *C. freundii* ULTN with mean transconjugation frequencies of 6.8 × 10^--3^--1.3 × 10^--6^ ([Supplementary Figure 3](#DS1){ref-type="supplementary-material"}).

![Transconjugation frequency during horizontal transfer of plasmids harboring *bla*~OXA--48~ from *E. coli* and *K. pneumoniae* clinical isolates to EC-J53. Each dot represents the frequency of a single transconjugation experiment, whereas the bars indicate the arithmetic mean of all experiments. **(A)** Transconjugation frequency from *E. coli* (EC) donors. The first four EC isolates harbor a 63 kb IncL *bla*~OXA--48~ plasmid with a Tn*1999* type plasmid ("63 kb IncL"), whereas EC3338 and EC9629 contain an IncF plasmid. ^∗∗∗^*P* \< 0.0001 (Mann--Whitney *U* test). **(B)** Transconjugation frequency from *K. pneumoniae* (KP) donors.](fmicb-10-02509-g001){#F1}

These results suggest that the 63 kb IncL *bla*~OXA--48~ plasmid occurs in different *K. pneumoniae* and *E. coli* lineages, has a broad host range in Enterobacterales and can be mobilized by efficient intraspecies and intergenus HGT with a high frequency of up to 5.7 × 10^--1^.

Virulence of OXA-48 Producing Clinical Isolates {#S3.SS3}
-----------------------------------------------

To evaluate virulence traits of clinical OXA-48 producing isolates, cytotoxicity toward human host cells and virulence in an *in vivo* infection model was investigated. First, human lung epithelial cells were infected with the 20 selected *E. coli* and *K. pneumoniae* isolates and the release of the intracellular enzyme LDH was measured as a surrogate marker for cytotoxicity ([Figure 2](#F2){ref-type="fig"}). After infection with *E. coli* isolates, the mean LDH activity compared to the positive control was 37.8 ± 24.1% ([Figure 2A](#F2){ref-type="fig"}). EC7215 was significantly more cytotoxic than all other strains (*P* \< 0.0001). LDH activity was high after infection with *K. pneumoniae* (mean: 76.0 ± 18.6%), indicating high species-specific membrane disintegration of *K. pneumoniae* compared to *E. coli* (*P* \< 0.0001). KP12536 was the most cytotoxic *K. pneumoniae* isolate, whereas KP2255 and KP1982 were significantly less cytotoxic compared to all other isolates (*P* \< 0.05).

![Cytotoxicity of OXA-48 isolates. **(A)** *E. coli* and **(B)** *K. pneumoniae*. LDH activity was measured from supernatants of infected A549 lung epithelial cells. Mean values from four independent experiments were compared to that of Triton X-100 which served as the positive control. Error bars represent standard deviations. ^∗∗^*P* \< 0.0001; ^∗^*P* \< 0.05 (Mann--Whitney *U* test).](fmicb-10-02509-g002){#F2}

To assess pathogenicity *in vivo*, the *G. mellonella* infection model was employed. To compare virulence across the isolates, time-kill curves were compared and median lethal dose (LD~50~) values were calculated. All *E. coli* and *K. pneumoniae* isolates caused a time- and dose-dependent killing of larvae ([Figure 3A](#F3){ref-type="fig"}). The mean LD~50~ was 4.9 for *E. coli* (range: 0.9--6.4) and 4.6 for *K. pneumoniae* (range: 2.5--6.1). Among *E. coli* isolates, EC7215 was highly virulent \[LD~50~ 0.9 (95% CI 0.63--1.14)\] compared to all other clinical strains and the reference strain J53, which was the least virulent \[LD~50~ 6.7 (95% CI 6.50--6.91)\]. In *K. pneumoniae*, the isolates KP980, KP1664, and KP12536 were significantly more virulent (LD~50~ 2.5--3.3) than the other clinical isolates and KP-PRZ (*P* \< 0.05). In summary, EC7215 and KP12536 were highly virulent in both assays ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

![Virulence of OXA-48 producing *Enterobacteriaceae* clinical isolates in the *Galleria mellonella in vivo* infection model. **(A)** Dose-dependent mortality of *G. mellonella* infected with KP980. Different cfu were injected into the larvae and survival was monitored for 72 h. Error bars show standard error of the mean. **(B)** Log median lethal dose (LD50) of clinical *E. coli* isolates. **(C)** LD50 of *K. pneumoniae* isolates. Mean values from three to four independent experiments with 12 larvae in each group are shown. Error bars represent the 95% confidence interval. ^∗∗∗^*P* \< 0.0001; ^∗^*P* \< 0.05 (Mann--Whitney *U* test).](fmicb-10-02509-g003){#F3}

*In silico* Analysis of Virulence {#S3.SS4}
---------------------------------

To investigate virulence mediated by the *bla*~OXA--48~ carrying plasmids *in silico*, the two highly virulent isolates EC7215 and KP12536 were sequenced by SMRT to obtain the complete sequence of the plasmids. The chromosome of EC7215 harbored a genome of 4,830,938 bp and a GC content of 50.8%, compared to 5,323,688 bp and 57.5% in KP12536. Both isolates contained an identical *bla*~OXA--48~ encoding plasmid of 63,589 bp ([Figure 4](#F4){ref-type="fig"}), which showed a 99.9% similarity to strain KPN-El-Nr.7 ([@B7]). The plasmid contained 41 genes and 28 open reading frames (ORF) encoding hypothetical proteins of unknown function. Among the predicted genes located on the plasmid, no virulence gene could be detected by any of the virulence gene databases (see section "Materials and Methods").

![Plasmid map of pOXA-48 and comparison of plasmids harboring *bla*~OXA--48~ and the transposons Tn*1999.2* and Tn6237. Each ring represents the nucleotide sequence of a plasmid or the transposon Tn6237 as indicated by the color code. Sequences of pE71T (accession no. KC335143.1), pOXA-48a (JN626286.1), pCF29 (LN864820.1), and Tn6237 (HG977710.1) were retrieved from the NCBI nucleotide database. Gene annotation of the reference plasmid pOXA-48 EC7215 is shown in the outer ring. Tn*1999.2* indicates the transposon region on all plasmids in this graph. Colored arrows indicate *bla*~OXA--48~ (red), insertion elements (orange), genes for plasmid stabilization (gold), and replication (green), disrupted genes (gray) and genes of unknown function (*bla*ck).](fmicb-10-02509-g004){#F4}

Whole genome analysis demonstrated that *E. coli* isolates harbored 70--122 genes associated with virulence, while *K. pneumoniae* isolates possessed 42--59 virulence genes and were less diverse regarding the presence of virulence genes ([Supplementary Figures 1](#DS1){ref-type="supplementary-material"}, [2](#DS1){ref-type="supplementary-material"}). Analysis of all thirteen isolates sequenced by SMRT showed that the vast majority of virulence genes was located on the chromosome, whereas only five different virulence genes were identified on plasmids which, however, did not harbor *bla*~OXA--48~. *E. coli* isolates harbored genes encoding virulence factors of different cellular function, e.g., adhesion, invasion, effector protein secretion, and the pathogenicity island PAIII~CFT073~. The virulence factors *wabG* and *uge*, which are important for host colonization and virulence and *kfu* which is involved in ion homeostasis, were present in all *K. pneumoniae* clinical isolates. Twenty-one virulence genes were detected in all isolates, e.g., the adhesin *focA* or the toxin *astA* which is commonly found in enterohemorrhagic *E. coli* (EHEC) and enteroaggregative *E. coli* (EAggEC). The mean number of virulence genes was 101 in *E. coli* and 47 in *K. pneumoniae* isolates. The isolates with the highest virulence in the *Galleria* model, *E. coli* EC7215 (86 virulence genes) and *K. pneumoniae* KP1664 (42 virulence genes) did not show higher numbers or distinct patterns of virulence genes compared to other isolates of the same species. In contrast, more virulence genes were found in EC1639 (122 virulence genes), which was isolated from a blood stream infection, but which neither showed a higher cytotoxicity nor a lower LD~50~ compared to the other isolates.

Virulence and Fitness of *bla*~OXA--48~ Harboring Transconjugants {#S3.SS5}
-----------------------------------------------------------------

The plasmid pOXA-48 EC7215 contained 28 ORFs of unknown function which potentially could encode for proteins mediating virulence or fitness. Therefore, transconjugants carrying *bla*~OXA--48~ (Tc) were used to investigate the impact of pOXA-48 on pathogenicity and fitness and compared to their isogenic *E. coli* and *K. pneumoniae* parental strains.

The infection of A549 cells with EC-J53 and J53 transconjugants harboring pOXA-48 from EC7215 (J53 Tc7215) and from KP12536 (J53 Tc12536) caused a LDH activity of 0.29 ± 0.06, 0.28 ± 0.05, and 0.30 ± 0.07, respectively, thereby showing no effect of pOXA-48 carriage on cytotoxicity ([Figure 5A](#F5){ref-type="fig"}). Likewise, carriage of pOXA-48 in *K. pneumoniae* Tc and parental strains did not alter cytotoxicity toward A549 cells. In comparison, the clinical strains EC7215 (LDH 0.96 ± 0.04) and KP12536 (LDH 0.92 ± 0.05) were significantly more cytotoxic than all transconjugants (*P* \< 0.01).

![Impact of pOXA-48 carriage on virulence and fitness. Cytotoxicity, virulence, and growth kinetics of clinical isolates EC7215 and KP12536 harboring pOXA-48, acceptor strains J53 and PRZ, and pOXA-48 transconjugants (Tc) were analyzed. **(A)** Cytotoxicity was determined by the LDH assay and **(B)** virulence by *G. mellonella* infection experiments as described above. **(C)** Doubling times were calculated from growth kinetics. An EC-J53 control strain ("J53 mcr-1") harboring the plasmid pKP2442-mcr-1, whose carriage causes a fitness loss, was used as a control ([@B36]). Bars represent the mean (*n* = 4). Error bars denote standard error **(A,C)** or the 95% CI **(B)**. n.s., no statistically significant differences as determined by the Mann--Whitney *U* test. **(D)** Dynamics of replicate competition experiments for EC-J53 and transconjugants containing the natural plasmid pOXA-48. The ratio of resistant versus susceptible cfu is shown (mean values from four independent experiments). Error bars denote the standard deviation of mean cfu counts.](fmicb-10-02509-g005){#F5}

To further explore virulence mediated by OXA-48, *G. mellonella* larvae were infected with transconjugants and their isogenic parental strains ([Figure 5B](#F5){ref-type="fig"}). LD~50~ values were similar for EC-J53 Tc (log LD~50~ = 6.65 ± 0.10 and 6.76 ± 0.18) and the parental strain (log LD~50~ = 6.71 ± 0.10), *P* = 0.74, and *P* = 0.98, respectively. Likewise, carriage of pOXA-48 in KP-PRZ did not have a significant impact on LD~50~ values, indicating no substantial effect of *bla*~OXA--48~ expression on virulence in *G. mellonella* (*P* = 0.85 and *P* = 0.73). In summary, the acquisition of pOXA-48 did not result in higher cytotoxicity or *in vivo* virulence.

Impact of pOXA-48 on Bacterial Fitness {#S3.SS6}
--------------------------------------

To analyze the impact of the acquisition of pOXA-48 on fitness, growth kinetics were compared between EC-J53 Tc7215 and Tc12536 and their parental strains ([Figure 5C](#F5){ref-type="fig"}). Doubling times were 42.4 ± 1.9 min for J53, 41.5 ± 0.8 min for J53 Tc7215, and 41.8 ± 1.0 min for J53 Tc12536 (*P* \> 0.05). In contrast, transconjugants harboring the plasmid pKP2442 containing the colistin resistance gene *mcr-1* had a doubling time of 46.9 min (*P* = 0.0095), indicating a loss of fitness ([@B36]). In KP-PRZ, transconjugants grew as fast as the parental strain (doubling times: 32.0 ± 1.8 min for PRZ, 33.5 ± 0.6 min for PRZ Tc12536, and 33.3 ± 2.0 min for PRZ Tc7215, *P* \> 0.05). In conclusion, acquisition of pOXA-48 did not have an impact on the doubling time when compared to the parental strains.

In addition, pairwise competitive growth experiments using minimal media were performed to further assess the impact of pOXA-48 on bacterial fitness. For this purpose, *E. coli* transconjugant J53 Tc7215 competed with its isogenic parental strain EC-J53 ([Figure 5D](#F5){ref-type="fig"}) and only a minor impact on fitness was recorded in the absence of antibiotics (selection rate constant s = −0.18 ± 0.02).

To assess plasmid stability, the plasmid loss of transconjugants EC-J53 Tc7215 and KP-PRZ Tc7215 was assessed by serial subcultures in antibiotic-free medium. In *E. coli*, the ratio of cells with and without plasmid was 1.026 ± 0.035 and 0.999 ± 0.156 in KP-PRZ, indicating a stable insertion of pOXA-48 with no plasmid loss.

Discussion {#S4}
==========

The successful dissemination of OXA-48 producing isolates is currently not completely understood. In contrast to other successful β-lactamase producing clonal lineages (e.g., *K. pneumoniae* KPC-2 ST258 or *E. coli* CTX-M-15 ST131), OXA-48 isolates belong to different STs but frequently harbor similar plasmids ([@B3]; [@B32]). In this study, 35 OXA-48 producing *E. coli* and *K. pneumoniae* clinical isolates were molecularly characterized and factors involved in dissemination and virulence were investigated *in silico*, *in vitro*, and *in vivo*.

Antibiotic susceptibility, resistance determinants and STs were highly diverse in the isolates investigated and did not correlate with virulence properties. In contrast, all *K. pneumoniae* and the majority of *E. coli* isolates harbored the same *bla*~OXA--48~ encoding 63 kb IncL plasmid, which was highly transmissible in both intraspecies and intergenus transconjugation assays. This plasmid was highly similar to the first isolate of OXA-48 in Turkey in 2001 ([@B30]) and the isolates KPN-El-Nr.7 from Switzerland ([@B7]). In contrast to the first description with Tn*1999* in 2001, most of our clinical isolates harbored a Tn*1999.2* transposon. Isolates with Tn*1999.2* have been reported to hydrolyze imipenem at higher rates than isolates carrying Tn*1999* due to increased expression of *bla*~OXA--48~ ([@B8]). Genetic support of *bla*~OXA--48~ was more diverse in *E. coli* with *bla*~OXA--48~ being located on the chromosome or on different plasmids including non-IncL variants. These non-IncL plasmids could be mobilized with much lower frequencies of only 10^--7^ compared to 10^--3^ for IncL plasmids, indicating that dissemination of *bla*~OXA--48~ is facilitated by the 63 kb sized IncL plasmid. The OXA-48 transposon structures on these non-IncL plasmids consisted of fragments of the chromosomally located Tn*6237*. However, IS*1R* sequences were truncated by additional mobile genetic elements in two of three plasmids, leading to a likely dysfunctional transposon structure. In the third IncF plasmid, a 3,360 bp fragment of Tn*6237* was found, forming a presumable intact and mobile transposon structure flanked by two IS*1R* sequences, which might be mobilizable into other plasmids or the chromosome. The high conjugation frequency of this plasmid has been attributed to the disruption of the *tir* gene, encoding a transfer inhibition protein, by insertion of the Tn*1999* in pOXA-48 ([@B31]).

Transconjugants showed high plasmid stabilities in the absence of antibiotic pressure. Furthermore, the 63 kb plasmid could also be conjugated to other Enterobacterales species such as *E. cloacae*, *S. marcescens*, or *C. freundii*, indicating a broad host range. This is also evidenced by reports of OXA-48 expressing clinical isolates of different species ([@B12]; [@B9]; [@B14]). These properties might lead to persistence of OXA-48 in environmental niches, healthy humans and animals without antibiotic pressure, contributing to further dissemination ([@B33]).

Because of the overwhelming epidemiological success of OXA-48, several studies previously suggested that OXA-48 does not only confer resistance to beta-lactams but is also associated with bacterial virulence and fitness ([@B3], [@B4]; [@B11]). To address this hypothesis, the LDH cytotoxicity assay using A549 human lung epithelial cells and the *G. mellonella in vivo* infection model were chosen. These two infection systems have been successfully used to compare virulence across strains from different isolation sites, to identify virulence factors and to analyze the impact of antibiotic resistance genes on fitness and virulence ([@B22]; [@B10]; [@B18]; [@B36]). Even though different virulence properties are analyzed by the LDH assay and the *G. mellonella* infection, a positive correlation between these infection models could be observed for both *E. coli* and *K. pneumoniae* in our study (*R* = 0.43 and *R* = 0.51, respectively).

The clinical isolates were highly diverse in their ability to damage human A549 cells, with LDH release ranging from 16.5 to 96.1% compared to the positive control. *K. pneumoniae* isolates were on average more cytotoxic compared to *E. coli* isolates indicating species-specific virulence ([Figure 2](#F2){ref-type="fig"}). However, EC7215 and KP12536 were the most cytotoxic isolates from the two species. Likewise, these two isolates were highly virulent in the *Galleria* assay. For example, just 8 cfu of EC7215 were able to kill 50% of larvae after 24 h ([Figure 3](#F3){ref-type="fig"}). [@B3], [@B4] and [@B11] reported that the presence of virulence genes, e.g., *pap*, *sfa*/*foc*, *hly*, and *afa*/*dra* are correlated with a virulent phenotype when analyzing eight isolates. However, when analyzing 20 isolates neither of these factors correlated with increased virulence or the numbers of virulence genes ([Supplementary Figures 4](#DS1){ref-type="supplementary-material"}, [5](#DS1){ref-type="supplementary-material"}).

Since the dissemination of OXA-48 is not driven by a single clone but rather by the highly prevalent 63 kb-sized IncL plasmid, we investigated the impact of pOXA-48 on virulence and fitness employing isogenic OXA-48-expressing *E. coli* and *K. pneumoniae* transconjugants and parental strains lacking OXA-48. We completely sequenced pOXA-48 but could not identify any genes with known association to virulence or fitness. Yet, 28 ORFs of unknown function were found which hypothetically could have an impact on virulence. However, survival of larvae was not different in transconjugants harboring pOXA-48 compared with the plasmid-free parental strains. Likewise, pOXA-48 carriage did not influence cytotoxicity toward human cells. This is in line with the observation that most of the clinical isolates displayed different virulence phenotypes but harbored the same OXA-48 plasmid. Even though no effect of the 63 kb IncL pOXA-48 was observed in the strains J53 and PRZ, it cannot be excluded that pOXA-48 contributes to virulence in other host strains, since the plasmid-encoded hypothetical ORFs may uniquely interact with other bacterial hosts. Hence, future studies should analyze the impact of pOXA-48 on virulence in additional host strains and also plasmid-cured clinical isolates.

This work has some limitations. Clinical isolates from two large tertiary care hospitals were used, which might not be representative for the whole country. Furthermore, it is not possible to transfer the virulence and fitness data from *in vitro* and *in vivo* model systems directly to a clinical setting. For example, the bacterial isolates may have organ-specific adaptations during infection in patients which cannot be monitored with our infection models, or the uptake of the IncL plasmid into *E. coli* J53 may not accurately recapitulate transmissibility in real clinical settings. The *in vitro* fitness assay allows the comparison of different isolates under standardized conditions. However, the fitness observed is influenced by the choice of media and can therefore not fully comparable to the clinical situation where different nutrient conditions are present and other, more complex factors like the immune system could further influence growth. Nevertheless, to the best of our knowledge this is the most comprehensive study on OXA-48 clinical isolates and plasmids from Germany. Compared to previous studies, we investigated HGT and virulence of OXA-48 producers employing a large number of isolates using *in vitro, in vivo*, and *in silico* methods. Furthermore, we could demonstrate for the first time that the 63 kb IncL plasmid which is disseminated worldwide can be transferred more efficiently compared to IncF plasmids, which might be a reason for its successful dissemination. In addition, acquisition of the 63 kb OXA-48 plasmid had only a minor impact on the fitness of EC-J53 in the competitive fitness assay and also did not lead to impaired growth *in vitro*. This is in contrast to other carbapenemases like NDM-1, which resulted in a highly decreased fitness of EC-J53 ([@B18]). The high prevalence and rapid dissemination of OXA-48 can therefore be rather attributed to a low fitness burden and high plasmid stability combined with a highly efficient HGT of the 63 kb IncL plasmid and not increased fitness or virulence.
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